Cargando…

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse with drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jasmine, Guanizo, Aleks C., Jakasekara, W. Samantha N., Inampudi, Chaitanya, Luong, Quinton, Garama, Daniel J., Alamgeer, Muhammad, Thakur, Nishant, DeVeer, Michael, Ganju, Vinod, Watkins, D. Neil, Cain, Jason E., Gough, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131464/
https://www.ncbi.nlm.nih.gov/pubmed/37098540
http://dx.doi.org/10.1186/s13046-023-02678-1
_version_ 1785031183093989376
author Chen, Jasmine
Guanizo, Aleks C.
Jakasekara, W. Samantha N.
Inampudi, Chaitanya
Luong, Quinton
Garama, Daniel J.
Alamgeer, Muhammad
Thakur, Nishant
DeVeer, Michael
Ganju, Vinod
Watkins, D. Neil
Cain, Jason E.
Gough, Daniel J.
author_facet Chen, Jasmine
Guanizo, Aleks C.
Jakasekara, W. Samantha N.
Inampudi, Chaitanya
Luong, Quinton
Garama, Daniel J.
Alamgeer, Muhammad
Thakur, Nishant
DeVeer, Michael
Ganju, Vinod
Watkins, D. Neil
Cain, Jason E.
Gough, Daniel J.
author_sort Chen, Jasmine
collection PubMed
description BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse with drug resistant disease. Elevated MYC expression is common in SCLC and has been associated with platinum resistance. This study evaluates the capacity of MYC to drive platinum resistance and through screening identifies a drug capable of reducing MYC expression and overcoming resistance. METHODS: Elevated MYC expression following the acquisition of platinum resistance in vitro and in vivo was assessed. Moreover, the capacity of enforced MYC expression to drive platinum resistance was defined in SCLC cell lines and in a genetically engineered mouse model that expresses MYC specifically in lung tumors. High throughput drug screening was used to identify drugs able to kill MYC-expressing, platinum resistant cell lines. The capacity of this drug to treat SCLC was defined in vivo in both transplant models using cell lines and patient derived xenografts and in combination with platinum and etoposide chemotherapy in an autochthonous mouse model of platinum resistant SCLC. RESULTS: MYC expression is elevated following the acquisition of platinum resistance and constitutively high MYC expression drives platinum resistance in vitro and in vivo. We show that fimepinostat decreases MYC expression and that it is an effective single agent treatment for SCLC in vitro and in vivo. Indeed, fimepinostat is as effective as platinum-etoposide treatment in vivo. Importantly, when combined with platinum and etoposide, fimepinostat achieves a significant increase in survival. CONCLUSIONS: MYC is a potent driver of platinum resistance in SCLC that is effectively treated with fimepinostat. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02678-1.
format Online
Article
Text
id pubmed-10131464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101314642023-04-27 MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat Chen, Jasmine Guanizo, Aleks C. Jakasekara, W. Samantha N. Inampudi, Chaitanya Luong, Quinton Garama, Daniel J. Alamgeer, Muhammad Thakur, Nishant DeVeer, Michael Ganju, Vinod Watkins, D. Neil Cain, Jason E. Gough, Daniel J. J Exp Clin Cancer Res Research BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse with drug resistant disease. Elevated MYC expression is common in SCLC and has been associated with platinum resistance. This study evaluates the capacity of MYC to drive platinum resistance and through screening identifies a drug capable of reducing MYC expression and overcoming resistance. METHODS: Elevated MYC expression following the acquisition of platinum resistance in vitro and in vivo was assessed. Moreover, the capacity of enforced MYC expression to drive platinum resistance was defined in SCLC cell lines and in a genetically engineered mouse model that expresses MYC specifically in lung tumors. High throughput drug screening was used to identify drugs able to kill MYC-expressing, platinum resistant cell lines. The capacity of this drug to treat SCLC was defined in vivo in both transplant models using cell lines and patient derived xenografts and in combination with platinum and etoposide chemotherapy in an autochthonous mouse model of platinum resistant SCLC. RESULTS: MYC expression is elevated following the acquisition of platinum resistance and constitutively high MYC expression drives platinum resistance in vitro and in vivo. We show that fimepinostat decreases MYC expression and that it is an effective single agent treatment for SCLC in vitro and in vivo. Indeed, fimepinostat is as effective as platinum-etoposide treatment in vivo. Importantly, when combined with platinum and etoposide, fimepinostat achieves a significant increase in survival. CONCLUSIONS: MYC is a potent driver of platinum resistance in SCLC that is effectively treated with fimepinostat. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02678-1. BioMed Central 2023-04-26 /pmc/articles/PMC10131464/ /pubmed/37098540 http://dx.doi.org/10.1186/s13046-023-02678-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Jasmine
Guanizo, Aleks C.
Jakasekara, W. Samantha N.
Inampudi, Chaitanya
Luong, Quinton
Garama, Daniel J.
Alamgeer, Muhammad
Thakur, Nishant
DeVeer, Michael
Ganju, Vinod
Watkins, D. Neil
Cain, Jason E.
Gough, Daniel J.
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title_full MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title_fullStr MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title_full_unstemmed MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title_short MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
title_sort myc drives platinum resistant sclc that is overcome by the dual pi3k-hdac inhibitor fimepinostat
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131464/
https://www.ncbi.nlm.nih.gov/pubmed/37098540
http://dx.doi.org/10.1186/s13046-023-02678-1
work_keys_str_mv AT chenjasmine mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT guanizoaleksc mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT jakasekarawsamanthan mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT inampudichaitanya mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT luongquinton mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT garamadanielj mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT alamgeermuhammad mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT thakurnishant mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT deveermichael mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT ganjuvinod mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT watkinsdneil mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT cainjasone mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat
AT goughdanielj mycdrivesplatinumresistantsclcthatisovercomebythedualpi3khdacinhibitorfimepinostat